1170931-79-9Relevant articles and documents
The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis
Cao, Shengtian,Li, Jing,Lin, Runfeng,Wang, Xiaojun,Xu, Juan,Yang, Wen,Yang, Xinye,Zhang, Jiancun,Zhang, Zheng,Zuo, Yinglin
supporting information, p. 1222 - 1231 (2021/11/02)
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, th